Observational Study of Safety of Flu Cell Culture Derived Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Vaccine
NCT01037855 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4028
Last updated 2017-03-14
Summary
This is an observational study of safety and occurrence of influenza-like illness following administration of flu cell culture derived adjuvanted swine origin A (H1N1) pandemic subunit vaccine in subjects 6 months of age and older.
Conditions
- Novel Influenza A (H1N1)
- A New Flu Virus of Swine Origin
Interventions
- OTHER
-
Non-intervention observational study
Non-intervention observational study
Sponsors & Collaborators
-
Novartis Vaccines
lead INDUSTRY
Eligibility
- Min Age
- 6 Months
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2009-12-31
- Primary Completion
- 2010-06-30
- Completion
- 2011-01-31
Countries
- Chile
- Colombia
- Germany
- Switzerland
Study Locations
More Related Trials
-
Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects From 6 Months to 17 Years of Age
NCT00971100 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Swine-Origin A/H1N1 Influenza Non-Adjuvanted Vaccine in Healthy Adults in India
NCT01053143 ·Status: COMPLETED ·Phase: PHASE3
-
Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects
NCT01342796 ·Status: COMPLETED ·Phase: PHASE2
-
Study on the Immunogenicity and Tolerability of Influsplit SSW® 2005/2006 in Children Aged 6 - 13 Years
NCT00372255 ·Status: COMPLETED ·Phase: PHASE4
-
Immunogenicity, Tolerability and Safety of One or Two Doses of an Adjuvanted Swine-origin A H1N1 Influenza Vaccine in Healthy Subjects 18 or More Years of Age Both Vaccinated and Not Yet Vaccinated Against Seasonal Influenza 2009/10
NCT00992212 ·Status: COMPLETED ·Phase: PHASE2
-
Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age
NCT00970177 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity of One Dose of a Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture Administered to Adult and Elderly Subjects
NCT01422512 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity of Trivalent Subunit Influenza Vaccine Produced in Mammalian Cell Culture Using the Strain Composition 2007/2008
NCT00511914 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above
NCT01640314 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety of FluBlok Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Pediatrics
NCT00336453 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety Study of CSL Limited's Influenza Virus Vaccine in the Paediatric Population Aged >= 6 Months to < 18 Years
NCT00825162 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children, Adolescents and Adults (3 to 64 Years)
NCT00973700 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety of V70P5 Revaccination Subjects
NCT01210898 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children
NCT01776554 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Immunogenicity of One Dose of an Inactivated Trivalent Sub-unit Influenza Vaccine Administered to Non-elderly Adult and Elderly Subjects
NCT01357265 ·Status: COMPLETED ·Phase: PHASE2
-
Swine Flu (Novel Influenza A H1N1) Vaccine Study
NCT00980850 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)
NCT00971321 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years)
NCT00972816 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok
NCT00539981 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy European Adults and the Elderly
NCT00954798 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Inactivated Swine-Origin A/H1N1 Influenza Vaccines in Healthy European Subjects Aged 3 to 17 Years
NCT00956202 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 1b Influenza Vaccine Study in Healthy Subjects
NCT01181336 ·Status: COMPLETED ·Phase: PHASE1
-
Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine (Egg-Derived) in Healthy Subjects From 6 Months to 17 Years of Age
NCT00971542 ·Status: COMPLETED ·Phase: PHASE3
-
Drug Use Investigation for Cell-culture Derived Influenza A (H1N1) Emulsion HA Vaccine
NCT01098786 ·Status: COMPLETED
-
Evaluate the Immunogenicity and Safety of the 2011-2012 Vaccine Against Seasonal Influenza on Pregnant Women
NCT01577316 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3